Comparison of serum treatments to remove nonspecific inhibitors from chicken sera for the hemagglutination inhibition test with inactivated H5N1 and H9N2 avian<i>Influenza A virus</i>subtypes

Kim, Hye-Ryoung; Lee, Kyoung-Ki; Kwon, Yong-Kuk; Kang, Min-Su; Moon, Oun-Kyung; Park, Choi‐Kyu

doi:10.1177/1040638712452732

Cited by 4 publications

(5 citation statements)

References 23 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the H9N2 avian virus subtype is generally not highly pathogenic for avian species, it has been associated with severe morbidity and mortality in poultry following coinfection with other pathogens [11, 12]. Recent findings indicate that the H5N1 viruses responsible for severe human disease contain genetic rearrangements that include several genes from obtained avian H9N2 viruses [13].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

et al. 2016

View full text Add to dashboard Cite

BackgroundThe avian influenza virus (AIV) can cross species barriers and expand its host range from birds to mammals, even humans. Avian influenza is characterized by pronounced activation of the proinflammatory cytokine cascade, which perpetuates the inflammatory response, leading to persistent systemic inflammatory response syndrome and pulmonary infection in animals and humans. There are currently no specific treatment strategies for avian influenza.MethodsWe hypothesized that mesenchymal stromal cells (MSCs) would have beneficial effects in the treatment of H9N2 AIV-induced acute lung injury in mice. Six- to 8-week-old C57BL/6 mice were infected intranasally with 1 × 104 MID50 of A/HONG KONG/2108/2003 [H9N2 (HK)] H9N2 virus to induce acute lung injury. After 30 min, syngeneic MSCs were delivered through the caudal vein. Three days after infection, we measured the survival rate, lung weight, arterial blood gas, and cytokines in both bronchoalveolar lavage fluid (BALF) and serum, and assessed pathological changes to the lungs.ResultsMSC administration significantly palliated H9N2 AIV-induced pulmonary inflammation by reducing chemokines and proinflammatory cytokines levels, as well as reducing inflammatory cell recruit into the lungs. Thus, H9N2 AIV-induced lung injury was markedly alleviated in mice treated with MSCs. Lung histopathology and arterial blood gas analysis were improved in mice with H9N2 AIV-induced lung injury following MSC treatment.ConclusionsMSC treatment significantly reduces H9N2 AIV-induced acute lung injury in mice and is associated with reduced pulmonary inflammation. These results indicate a potential role for MSC therapy in the treatment of clinical avian influenza.

show abstract

Section: Introductionmentioning

confidence: 99%

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

et al. 2016

View full text Add to dashboard Cite

show abstract

“…4G to J). Sera used for both HAI and plaque reduction assays were treated with sialic acid receptor-destroying enzyme (RDE) to eliminate nonspecific inhibition of viral binding mediated by serum components other than antibodies (31, 32). …”

Section: Resultsmentioning

confidence: 99%

Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs

Harding

Heaton

Dumm

et al. 2017

mBio

View full text Add to dashboard Cite

Influenza virus vaccine production is currently limited by the ability to grow circulating human strains in chicken eggs or in cell culture. To facilitate cost-effective growth, vaccine strains are serially passaged under production conditions, which frequently results in mutations of the major antigenic protein, the viral hemagglutinin (HA). Human vaccination with an antigenically drifted strain is known to contribute to poor vaccine efficacy. To address this problem, we developed a replication-competent influenza A virus (IAV) with an artificial genomic organization that allowed the incorporation of two independent and functional HA proteins with different growth requirements onto the same virion. Vaccination with these viruses induced protective immunity against both strains from which the HA proteins were derived, and the magnitude of the response was as high as or higher than vaccination with either of the monovalent parental strains alone. Dual-HA viruses also displayed remarkable antigenic stability; even when using an HA protein known to be highly unstable during growth in eggs, we observed high-titer virus amplification without a single adaptive mutation. Thus, the viral genomic design described in this work can be used to grow influenza virus vaccines to high titers without introducing antigenic mutations.

show abstract

“…10 This result could also be the consequence of nonspecific inhibition, which commonly yields false-positives in HI testing. 5,7 In 2007, the seroprevalence of CIV H3N2 was found to be ~0.48% in Korean dogs. 6 In 2010, 34.8% of tested dogs in South Korea were seropositive for CIV H3N2; none of the tested cats were seropositive.…”

Section: Brief-report2019mentioning

confidence: 99%

“…10 This result could also be the consequence of nonspecific inhibition, which commonly yields false-positives in HI testing. 5,7…”

mentioning

confidence: 99%

Serologic investigation of exposure to influenza A virus H3N2 infection in dogs and cats in the United States

et al. 2019

View full text Add to dashboard Cite

We investigated, in a cross-sectional study, the prevalence of antibodies against canine influenza A virus (CIV) H3N2 in serum samples collected from dogs and cats using a commercial ELISA and a hemagglutination inhibition (HI) test. Samples were obtained from 519 cats and dogs from 13 states within the United States. Data were analyzed for potential risk factors with positive sera (vs. negative sera) by logistic regression. Odds ratios and their 95% confidence intervals (CIs) were calculated by exponentiation of the regression coefficients. Ten dogs (2.21%; 95% CI: 1.05-3.98%) and 6 cats (8.96%; 95% CI: 3.36-18.48%) tested seropositive for CIV H3N2 by HI. One feline sample (1.49%; 95% CI: 0.04-8.04%) and 16 canine samples (3.53%; 95% CI: 2.01-5.61%) tested seropositive by ELISA for influenza A virus. There were no apparent associations between seropositivity and putative risk factors. All positive animals were from Indiana or Illinois; however, CIV H3N2 seroprevalence was not common in Illinois and Indiana.

show abstract

Comparison of serum treatments to remove nonspecific inhibitors from chicken sera for the hemagglutination inhibition test with inactivated H5N1 and H9N2 avianInfluenza A virussubtypes

Cited by 4 publications

References 23 publications

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs

Serologic investigation of exposure to influenza A virus H3N2 infection in dogs and cats in the United States

Contact Info

Product

Resources

About